Teva Puts End Of 2022 Ambition On Nationwide US Opioids Settlement
‘We Believe We’re Getting Closer,’ Says CEO Kåre Schultz
After adding more than $1bn to its legal settlement contingency in Q1, Teva has given its clearest indication yet for when it expects to announce a nationwide deal in the US to settle opioid-related claims. The Israeli firm is facing two bench trials in the coming weeks and months but is optimistic on that front also.
